Drugs / Immunoregulatory Dendritic Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02354911 | Oct 2015 → Feb 2024 | type 1 diabetes mellitus | DiaVacs, Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immunoregulatory Dendritic Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02354911 ↗ |
| Action | Inhibit | “antisense DNA oligonucleotides targeting the primary transcripts of CD40, CD80 and CD86” NCT02354911 ↗ |
| Modality | Cell therapy | “Autologous dendritic cells harvested by leukapheresis and engineered ex vivo” NCT02354911 ↗ |
| Route | Other | “administered via blinded intradermal injection” NCT02354911 ↗ |
| Target | CD40 | “antisense DNA oligonucleotides targeting the primary transcripts of CD40” NCT02354911 ↗ |